APSARD January 1 - 2024 Supporting materials Efficacy and Safety of Once-Daily Extended-Release Centanafadine for the Treatment of Attention-Deficit/ Hyperactivity Disorder in Adolescents Aged 13–17 Years Efficacy and Safety of Once-Daily Extended-Release Centanafadine for the Treatment of Attention-Deficit/ Hyperactivity Disorder in Children Aged 6–12 Years 52-Week Open-Label Safety and Tolerability of Centanafadine Sustained Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder Patient-Reported Adult ADHD Symptom Improvements With Centanafadine Sustained Release Correlate With Objective Clinician-Based Efficacy Measures Centanafadine Sustained Release Is Efficacious in Patients With Adult ADHD, Regardless of Their Treatment History A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization Centanafadine Sustained Release Is Efficacious in the Treatment of Adult ADHD Across Disease Severities